menu search

Merck blockbuster shows promise in bladder cancer

Merck & Co Inc (NYSE:MRK) has announced promising results from its phase III clinical trial of its blockbuster cancer drug Keytruda in people with cer...

October 5, 2023, 8:43 am

Io biotech announces three poster presentations at the society for immunotherapy of cancer’s (sitc) 38th annual meeting

NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

October 3, 2023, 8:30 pm

23andme announces poster presentations on 23me-00610, an investigational antibody targeting cd200r1, at the society for immunotherapy of cancer’s (sitc) 2023 annual meeting

23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610 Phase 1/2a clinical trial in patients with advanced solid...

September 27, 2023, 8:05 pm

Cellectis to present pre-clinical data on multi-armored allogeneic muc1-car t-cells targeting triple-negative breast cancer at the society for immunotherapy of cancer (sitc) 38th annual meeting

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology com...

September 27, 2023, 4:30 pm

Iovance biotherapeutics to present clinical and pre-clinical data for tumor infiltrating lymphocyte (til) therapies at society for tumor immunotherapy of cancer's (sitc) 38th annual meeting

SAN CARLOS, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, de...

September 27, 2023, 4:01 pm

Coherus announces three presentations at the 38th annual meeting of the society for immunotherapy of cancer (sitc)

REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three...

September 27, 2023, 1:10 pm

Allogene therapeutics announces three poster presentations from its next generation allocar t™ platform at the society for immunotherapy of cancer (sitc) annual meeting

Spotlight on Novel, Targeted Technologies to Enhance Engraftment, Expansion and Persistence of AlloCAR T™ Cells Demonstration of Dagger™ Technolog...

September 27, 2023, 1:09 pm

Mink therapeutics to present data update from allogeneic inkt cells in solid tumors at sitc 2023

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discove...

September 27, 2023, 9:05 am

Crispr therapeutics to present at the society for immunotherapy of cancer (sitc) 38th annual meeting

ZUG, Switzerland and BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating tr...

September 27, 2023, 9:01 am

Pds biotech reschedules key opinion leader roundtable addressing current and future treatments for recurrent/metastatic hpv-positive hnscc and the potential application of pds0101

Event to be held on Tuesday, October 3 from 8:00 to 9:00 AM EDT PRINCETON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Na...

September 25, 2023, 12:00 pm

Kineta to present new preclinical data on lead anti-cd27 agonist antibody at aacr special conference on tumor immunology and immunotherapy

SEATTLE, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immu...

September 25, 2023, 9:30 am

Drugmaker merck says keytruda combination fails in lung cancer trial

Merck said on Friday its cancer immunotherapy Keytruda in combination with partner Eisai's drug failed ...

September 22, 2023, 7:09 am

Checkpoint therapeutics to participate in the cantor global healthcare conference

WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage ...

September 21, 2023, 8:30 am

Cancervax ceo ryan davies discusses the company’s growing pipeline of cancer treatments

The Company’s development pipeline now includes three projects with UCLA LEHI, Utah, Sept. 14, 2023 (GLOBE NEWSWIRE) — CancerVAX, Inc., a pre-clin...

September 14, 2023, 7:01 am

Imunon to host virtual r&d day on september 14th beginning at 4:00 p.m. et

Program will feature members of IMUNON executive management along with key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N...

September 7, 2023, 8:30 pm

Pds biotech to participate at the h.c. wainwright 25th annual global investment conference

PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage ...

September 6, 2023, 8:05 pm

Merck's (mrk) keytruda receives eu nod in gastric cancer

Following the approval, Merck's (MRK) Keytruda is the first immunotherapy approved in the EU for first-...

August 30, 2023, 1:31 pm

Coya therapeutics to present novel proof of concept exosome modification technology at the 5th exosome based therapeutic development summit in boston, ma on september 7, 2023

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing ...

August 25, 2023, 9:00 am

Roche reports inadvertent disclosure in lung cancer immunotherapy study

Swiss drug maker Roche said on Wednesday it had been made aware of an inadvertent disclosure in a study of its new ...

August 23, 2023, 2:10 am

Gilead sciences told by fda to pause patient enrollment in leukemia drug trials

Gilead Sciences, Inc. (NASDAQ:GILD) said the Food and Drug Administration (FDA) has put a clinical hold on its studies evaluating its investigation an...

August 21, 2023, 10:41 am


Search within

Pages Search Results: